Treffer: Gut Microbiota and Metabolic Alterations Associated with Heart Failure and Coronary Artery Disease.
Title:
Gut Microbiota and Metabolic Alterations Associated with Heart Failure and Coronary Artery Disease.
Authors:
Yafarova AA; National Medical Research Center for Therapy and Preventive Medicine, Petroverigskyj Lane 10, Bld. 3, 101990 Moscow, Russia., Dementeva EV; Federal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency, Pogodinskaya Str., 10/1, 119121 Moscow, Russia., Zlobovskaya OA; Federal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency, Pogodinskaya Str., 10/1, 119121 Moscow, Russia., Sheptulina AF; National Medical Research Center for Therapy and Preventive Medicine, Petroverigskyj Lane 10, Bld. 3, 101990 Moscow, Russia., Lopatukhina EV; Federal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency, Pogodinskaya Str., 10/1, 119121 Moscow, Russia., Timofeev YS; National Medical Research Center for Therapy and Preventive Medicine, Petroverigskyj Lane 10, Bld. 3, 101990 Moscow, Russia., Glazunova EV; Federal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency, Pogodinskaya Str., 10/1, 119121 Moscow, Russia., Lyundup AV; Endocrinology Research Centre, Dmitry Ulyanov St. 19, 117036 Moscow, Russia., Doludin YV; National Medical Research Center for Therapy and Preventive Medicine, Petroverigskyj Lane 10, Bld. 3, 101990 Moscow, Russia., Kiselev AR; National Medical Research Center for Therapy and Preventive Medicine, Petroverigskyj Lane 10, Bld. 3, 101990 Moscow, Russia., Shipulin GA; Federal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency, Pogodinskaya Str., 10/1, 119121 Moscow, Russia., Makarov VV; Federal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency, Pogodinskaya Str., 10/1, 119121 Moscow, Russia., Drapkina OM; National Medical Research Center for Therapy and Preventive Medicine, Petroverigskyj Lane 10, Bld. 3, 101990 Moscow, Russia., Yudin SM; Federal State Budgetary Institution «Centre for Strategic Planning and Management of Biomedical Health Risks» of the Federal Medical and Biological Agency, Pogodinskaya Str., 10/1, 119121 Moscow, Russia.
Source:
International journal of molecular sciences [Int J Mol Sci] 2024 Oct 20; Vol. 25 (20). Date of Electronic Publication: 2024 Oct 20.
Publication Type:
Journal Article
Language:
English
Journal Info:
Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Gastrointestinal Microbiome* , Coronary Artery Disease*/microbiology , Coronary Artery Disease*/metabolism , Heart Failure*/microbiology , Heart Failure*/metabolism, Humans ; Male ; Female ; Middle Aged ; Aged ; Cross-Sectional Studies ; Methylamines/metabolism ; Methylamines/blood ; Machine Learning ; Feces/microbiology ; High-Throughput Nucleotide Sequencing
References:
Am J Cardiol. 2022 Sep 1;178:26-34. (PMID: 35787338)
Mol Biomed. 2022 Oct 11;3(1):30. (PMID: 36219347)
Cardiovasc Res. 2024 Mar 30;120(4):372-384. (PMID: 38289866)
World J Gastroenterol. 2014 Nov 21;20(43):16062-78. (PMID: 25473158)
J Am Coll Cardiol. 2014 Nov 4;64(18):1908-14. (PMID: 25444145)
J Intern Med. 2015 Jun;277(6):717-26. (PMID: 25382824)
Front Microbiol. 2022 Jun 14;13:906920. (PMID: 35774450)
Exp Gerontol. 2023 Mar;173:112088. (PMID: 36646294)
FASEB J. 2020 Nov;34(11):14166-14181. (PMID: 32939880)
Circulation. 2023 Aug 8;148(6):459-472. (PMID: 37435755)
BMC Microbiol. 2023 Nov 3;23(1):320. (PMID: 37924005)
Microb Cell. 2023 Jan 13;10(2):36-48. (PMID: 36789351)
Ter Arkh. 2023 Aug 17;95(6):468-474. (PMID: 38158965)
Microb Pathog. 2024 Jul;192:106647. (PMID: 38788811)
J Card Fail. 2017 Sep;23(9):666-671. (PMID: 28688889)
mSystems. 2021 Oct 26;6(5):e0070321. (PMID: 34491083)
Therap Adv Gastroenterol. 2017 Dec 04;11:1756283X17743420. (PMID: 29383025)
EBioMedicine. 2022 Aug;82:104087. (PMID: 35797768)
BMC Cardiovasc Disord. 2020 Jan 9;20(1):7. (PMID: 31918665)
Front Cardiovasc Med. 2021 Oct 29;8:728724. (PMID: 34778397)
Sci Rep. 2020 Oct 29;10(1):18675. (PMID: 33122777)
J Atheroscler Thromb. 2016 Aug 1;23(8):908-21. (PMID: 26947598)
Best Pract Res Clin Endocrinol Metab. 2021 May;35(3):101492. (PMID: 33642219)
Appl Microbiol Biotechnol. 2017 Jan;101(1):47-64. (PMID: 27888332)
ESC Heart Fail. 2017 Aug;4(3):282-290. (PMID: 28772054)
J Acad Nutr Diet. 2023 Sep;123(9):1280-1288. (PMID: 37201748)
Front Physiol. 2021 May 14;12:686249. (PMID: 34054588)
Clin Res Cardiol. 2022 Jun;111(6):692-704. (PMID: 35220448)
NPJ Biofilms Microbiomes. 2022 Mar 10;8(1):11. (PMID: 35273169)
Hypertension. 2020 Nov;76(5):1555-1562. (PMID: 32909848)
Cell Rep. 2018 Jul 24;24(4):935-946. (PMID: 30044989)
mSystems. 2021 Aug 31;6(4):e0036321. (PMID: 34402645)
Microbiome. 2019 Apr 26;7(1):68. (PMID: 31027508)
J Cell Mol Med. 2019 Apr;23(4):2343-2350. (PMID: 30712327)
Clin Sci (Lond). 2018 Jan 11;132(1):85-91. (PMID: 29326279)
Medicine (Baltimore). 2023 Nov 10;102(45):e35795. (PMID: 37960774)
Metabolites. 2022 Nov 23;12(12):. (PMID: 36557203)
Semin Nephrol. 2018 Mar;38(2):193-205. (PMID: 29602401)
Rev Port Cardiol. 2023 Jun;42(6):543-551. (PMID: 36893840)
J Cardiovasc Dev Dis. 2023 Oct 07;10(10):. (PMID: 37887867)
Circ J. 2018 May 25;82(6):1640-1650. (PMID: 29607983)
Eur J Immunol. 2018 Apr;48(4):564-575. (PMID: 29230812)
Environ Microbiol. 2017 Jan;19(1):29-41. (PMID: 27928878)
Circ Heart Fail. 2021 Jun;14(6):e007909. (PMID: 34129361)
Front Microbiol. 2022 Nov 25;13:1002185. (PMID: 36504831)
Biomedicines. 2022 Oct 31;10(11):. (PMID: 36359282)
FEMS Microbiol Rev. 2014 Sep;38(5):996-1047. (PMID: 24861948)
Gut Microbes. 2019;10(3):270-288. (PMID: 30563420)
Int J Syst Evol Microbiol. 2012 Aug;62(Pt 8):1902-1907. (PMID: 22859731)
Br J Nutr. 2005 Nov;94(5):705-13. (PMID: 16277772)
Nutr Metab Cardiovasc Dis. 2020 Nov 27;30(12):2320-2327. (PMID: 32912784)
Cell Host Microbe. 2023 Apr 12;31(4):485-499. (PMID: 37054671)
Nat Rev Gastroenterol Hepatol. 2022 Dec;19(12):805-813. (PMID: 36050385)
Evid Based Complement Alternat Med. 2021 Dec 27;2021:7195082. (PMID: 34987598)
Sci Rep. 2019 Oct 30;9(1):15580. (PMID: 31666590)
Hum Microb J. 2019 Aug;13:. (PMID: 35506046)
Circulation. 2017 Apr 25;135(17):1671-1673. (PMID: 28438808)
Nutr Metab Cardiovasc Dis. 2021 Nov 29;31(12):3434-3448. (PMID: 34666915)
Curr Opin Microbiol. 2019 Aug;50:64-70. (PMID: 31693963)
PLoS One. 2017 Mar 22;12(3):e0174099. (PMID: 28328981)
Front Microbiol. 2022 Jan 31;12:813289. (PMID: 35173696)
Gastroenterol Hepatol (N Y). 2012 Jan;8(1):22-8. (PMID: 22347829)
Biomed Res Int. 2017;2017:3796359. (PMID: 28497047)
BMC Complement Med Ther. 2022 Mar 30;22(1):93. (PMID: 35354453)
Nat Commun. 2017 Oct 10;8(1):845. (PMID: 29018189)
ESC Heart Fail. 2020 Apr;7(2):456-466. (PMID: 31978943)
Mol Biomed. 2022 Oct 11;3(1):30. (PMID: 36219347)
Cardiovasc Res. 2024 Mar 30;120(4):372-384. (PMID: 38289866)
World J Gastroenterol. 2014 Nov 21;20(43):16062-78. (PMID: 25473158)
J Am Coll Cardiol. 2014 Nov 4;64(18):1908-14. (PMID: 25444145)
J Intern Med. 2015 Jun;277(6):717-26. (PMID: 25382824)
Front Microbiol. 2022 Jun 14;13:906920. (PMID: 35774450)
Exp Gerontol. 2023 Mar;173:112088. (PMID: 36646294)
FASEB J. 2020 Nov;34(11):14166-14181. (PMID: 32939880)
Circulation. 2023 Aug 8;148(6):459-472. (PMID: 37435755)
BMC Microbiol. 2023 Nov 3;23(1):320. (PMID: 37924005)
Microb Cell. 2023 Jan 13;10(2):36-48. (PMID: 36789351)
Ter Arkh. 2023 Aug 17;95(6):468-474. (PMID: 38158965)
Microb Pathog. 2024 Jul;192:106647. (PMID: 38788811)
J Card Fail. 2017 Sep;23(9):666-671. (PMID: 28688889)
mSystems. 2021 Oct 26;6(5):e0070321. (PMID: 34491083)
Therap Adv Gastroenterol. 2017 Dec 04;11:1756283X17743420. (PMID: 29383025)
EBioMedicine. 2022 Aug;82:104087. (PMID: 35797768)
BMC Cardiovasc Disord. 2020 Jan 9;20(1):7. (PMID: 31918665)
Front Cardiovasc Med. 2021 Oct 29;8:728724. (PMID: 34778397)
Sci Rep. 2020 Oct 29;10(1):18675. (PMID: 33122777)
J Atheroscler Thromb. 2016 Aug 1;23(8):908-21. (PMID: 26947598)
Best Pract Res Clin Endocrinol Metab. 2021 May;35(3):101492. (PMID: 33642219)
Appl Microbiol Biotechnol. 2017 Jan;101(1):47-64. (PMID: 27888332)
ESC Heart Fail. 2017 Aug;4(3):282-290. (PMID: 28772054)
J Acad Nutr Diet. 2023 Sep;123(9):1280-1288. (PMID: 37201748)
Front Physiol. 2021 May 14;12:686249. (PMID: 34054588)
Clin Res Cardiol. 2022 Jun;111(6):692-704. (PMID: 35220448)
NPJ Biofilms Microbiomes. 2022 Mar 10;8(1):11. (PMID: 35273169)
Hypertension. 2020 Nov;76(5):1555-1562. (PMID: 32909848)
Cell Rep. 2018 Jul 24;24(4):935-946. (PMID: 30044989)
mSystems. 2021 Aug 31;6(4):e0036321. (PMID: 34402645)
Microbiome. 2019 Apr 26;7(1):68. (PMID: 31027508)
J Cell Mol Med. 2019 Apr;23(4):2343-2350. (PMID: 30712327)
Clin Sci (Lond). 2018 Jan 11;132(1):85-91. (PMID: 29326279)
Medicine (Baltimore). 2023 Nov 10;102(45):e35795. (PMID: 37960774)
Metabolites. 2022 Nov 23;12(12):. (PMID: 36557203)
Semin Nephrol. 2018 Mar;38(2):193-205. (PMID: 29602401)
Rev Port Cardiol. 2023 Jun;42(6):543-551. (PMID: 36893840)
J Cardiovasc Dev Dis. 2023 Oct 07;10(10):. (PMID: 37887867)
Circ J. 2018 May 25;82(6):1640-1650. (PMID: 29607983)
Eur J Immunol. 2018 Apr;48(4):564-575. (PMID: 29230812)
Environ Microbiol. 2017 Jan;19(1):29-41. (PMID: 27928878)
Circ Heart Fail. 2021 Jun;14(6):e007909. (PMID: 34129361)
Front Microbiol. 2022 Nov 25;13:1002185. (PMID: 36504831)
Biomedicines. 2022 Oct 31;10(11):. (PMID: 36359282)
FEMS Microbiol Rev. 2014 Sep;38(5):996-1047. (PMID: 24861948)
Gut Microbes. 2019;10(3):270-288. (PMID: 30563420)
Int J Syst Evol Microbiol. 2012 Aug;62(Pt 8):1902-1907. (PMID: 22859731)
Br J Nutr. 2005 Nov;94(5):705-13. (PMID: 16277772)
Nutr Metab Cardiovasc Dis. 2020 Nov 27;30(12):2320-2327. (PMID: 32912784)
Cell Host Microbe. 2023 Apr 12;31(4):485-499. (PMID: 37054671)
Nat Rev Gastroenterol Hepatol. 2022 Dec;19(12):805-813. (PMID: 36050385)
Evid Based Complement Alternat Med. 2021 Dec 27;2021:7195082. (PMID: 34987598)
Sci Rep. 2019 Oct 30;9(1):15580. (PMID: 31666590)
Hum Microb J. 2019 Aug;13:. (PMID: 35506046)
Circulation. 2017 Apr 25;135(17):1671-1673. (PMID: 28438808)
Nutr Metab Cardiovasc Dis. 2021 Nov 29;31(12):3434-3448. (PMID: 34666915)
Curr Opin Microbiol. 2019 Aug;50:64-70. (PMID: 31693963)
PLoS One. 2017 Mar 22;12(3):e0174099. (PMID: 28328981)
Front Microbiol. 2022 Jan 31;12:813289. (PMID: 35173696)
Gastroenterol Hepatol (N Y). 2012 Jan;8(1):22-8. (PMID: 22347829)
Biomed Res Int. 2017;2017:3796359. (PMID: 28497047)
BMC Complement Med Ther. 2022 Mar 30;22(1):93. (PMID: 35354453)
Nat Commun. 2017 Oct 10;8(1):845. (PMID: 29018189)
ESC Heart Fail. 2020 Apr;7(2):456-466. (PMID: 31978943)
Grant Information:
075-15-2022-310 Ministry of Science and Higher Education of the Russian Federation; 388-00154-22-00 Ministry of Health of Russia
Contributed Indexing:
Keywords: alpha-diversity; beta-diversity; cardiovascular biomarkers; coronary artery disease; dysbiosis; gut microbiota; heart failure; trimethylamine-N-oxide
Substance Nomenclature:
0 (Methylamines)
FLD0K1SJ1A (trimethyloxamine)
FLD0K1SJ1A (trimethyloxamine)
Entry Date(s):
Date Created: 20241026 Date Completed: 20241026 Latest Revision: 20241028
Update Code:
20250114
PubMed Central ID:
PMC11508380
DOI:
10.3390/ijms252011295
PMID:
39457077
Database:
MEDLINE
Weitere Informationen
This study investigates the role of gut microbiota in cardiovascular diseases, with an additional focus on pro-atherogenic metabolites. We use advanced network analysis and machine learning techniques to identify key microbial features linked to coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF). This cross-sectional study included 189 participants divided into three groups: coronary artery disease ( n = 93), heart failure with reduced ejection fraction ( n = 43), and controls ( n = 53). Assessments included physical exams, echocardiography, dietary surveys, blood analysis, and fecal analysis. Gut microbiota composition was analyzed using next-generation sequencing (NGS) and quantitative polymerase chain reaction (qPCR). Statistical analysis methods for testing hypotheses and correlations, alpha and beta-diversity analyses, co-occurrence networks, and machine learning were conducted using Python libraries or R packages with multiple comparisons corrected using the Benjamini-Hochberg procedure. Significant gut microbiota alterations were observed, with higher Bacillota/Bacteroidota ratios in CAD and HFrEF groups compared to controls ( p < 0.001). Significant differences were observed in α-diversity indices (Pielou, Chao1, Faith) between disease groups and controls ( p < 0.001). β-diversity analyses also revealed distinct microbial profiles ( p = 0.0015). Interestingly, trimethylamine N-oxide (TMAO) levels were lower in CAD and HFrEF groups compared to controls ( p < 0.05), while indoxyl sulfate (IS) levels were comparable between the study groups. Co-occurrence network analysis and machine learning identified key microbial features linked to these conditions, highlighting complex interactions within the gut microbiota associated with cardiovascular disease.